全文获取类型
收费全文 | 5353篇 |
免费 | 495篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 141篇 |
妇产科学 | 156篇 |
基础医学 | 718篇 |
口腔科学 | 62篇 |
临床医学 | 469篇 |
内科学 | 1291篇 |
皮肤病学 | 74篇 |
神经病学 | 400篇 |
特种医学 | 157篇 |
外科学 | 803篇 |
综合类 | 123篇 |
一般理论 | 4篇 |
预防医学 | 290篇 |
眼科学 | 162篇 |
药学 | 366篇 |
中国医学 | 24篇 |
肿瘤学 | 587篇 |
出版年
2023年 | 46篇 |
2022年 | 101篇 |
2021年 | 174篇 |
2020年 | 132篇 |
2019年 | 199篇 |
2018年 | 181篇 |
2017年 | 146篇 |
2016年 | 147篇 |
2015年 | 198篇 |
2014年 | 233篇 |
2013年 | 254篇 |
2012年 | 372篇 |
2011年 | 381篇 |
2010年 | 218篇 |
2009年 | 176篇 |
2008年 | 292篇 |
2007年 | 289篇 |
2006年 | 276篇 |
2005年 | 248篇 |
2004年 | 223篇 |
2003年 | 217篇 |
2002年 | 190篇 |
2001年 | 114篇 |
2000年 | 123篇 |
1999年 | 83篇 |
1998年 | 44篇 |
1997年 | 32篇 |
1996年 | 33篇 |
1995年 | 21篇 |
1994年 | 27篇 |
1993年 | 24篇 |
1992年 | 61篇 |
1991年 | 60篇 |
1990年 | 79篇 |
1989年 | 50篇 |
1988年 | 54篇 |
1987年 | 55篇 |
1986年 | 39篇 |
1985年 | 48篇 |
1984年 | 35篇 |
1983年 | 27篇 |
1982年 | 17篇 |
1981年 | 17篇 |
1980年 | 18篇 |
1979年 | 20篇 |
1978年 | 18篇 |
1977年 | 13篇 |
1976年 | 15篇 |
1975年 | 11篇 |
1974年 | 11篇 |
排序方式: 共有5886条查询结果,搜索用时 15 毫秒
991.
Yee D 《BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy》2011,25(4):271-273
Joining cetuximab, sorafenib, afatinib, intedanib, and crizotinib in phase III development for non-small cell lung cancer (NSCLC) are ramucirumab (developed by ImClone, a subsidiary of Lilly), necitumumab (developed by ImClone and Bristol-Myers Squibb), and tivantinib (ARQ 197, developed by ArQule and Daiichi Sankyo). Necitumumab is a second-generation anti-EGFR monoclonal antibody (mAb) similar to cetuximab. Enrollment has been stopped in one of two necitumumab phase III trials because of safety concerns. Ramucirumab is an anti-VEGFR2 mAb targeting the same pathway as bevacizumab. Although the phase II safety data for ramucirumab appear better than the data for necitumumab, fewer phase III data are available. Tivantinib is a highly selective, orally available MET tyrosine kinase inhibitor. MET is overexpressed in 61% of NSCLC cases. Although tivantinib is the last of the three agents discussed here to enter phase III, its phase II results are the most robust. 相似文献
992.
993.
We report a novel synthetic biocompatible material: a conjugate with a fatty acid-substituted dextran decorated with cRGDfK peptide, which was used as a stable coating material instead of the conventional poly(ethylene glycol) for nanodrug preparation. This novel dextran-oleate-cRGDfK conjugate (DO-cRGDfk) could self-assemble into a micellar structure in aqueous solution, and was used as a surfactant to formulate nanodrug with poly(d,l-lactic-co-glycolic) acid as matrix to encapsulate paclitaxel with high drug-loading efficiency. The conjugate allowed the fabrication of nanodrug with a targeting moiety on its surface in a simple and robust step. The resultant nanoparticles could induce cellular apoptosis more effectively than that of the commercial paclitaxel formulation, Taxol. Thus, DO-cRGDfk could be used as an alternative to poly(ethylene glycol) as a biocompatible surface coating polymeric material for nanoparticle preparation. FROM THE CLINICAL EDITOR: The authors describe a novel synthetic biocompatible conjugate, which consists of a fatty acid-substituted dextran decorated with cRGDfK peptide. This conjugate was used as a stable coating material for nanodrug preparation, and can be used in place of conventional PEG. 相似文献
994.
995.
996.
997.
998.
Rebecca McGirr Shirley Hu Siu-Pok Yee Michael S. Kovacs Ting-Yim Lee Savita Dhanvantari 《Molecular imaging and biology》2011,13(5):962-972
Purpose
We have generated transgenic mouse lines expressing the positron emission tomography (PET) reporter gene, sr39tk, under the control of the mouse insulin I promoter (MIP-sr39tk) to image endogenous islets using PET. 相似文献999.